Additionally, the gene expression of HDAC4 (class IIA) and of SIRT3, SIRT5, SIRT6, and SIRT7 (class III) were significantly reduced and HDAC11 (class IV) was significantly increased in AML patients compared to healthy controls (Supplementary Figure S1A). This evidence concerns the gene SIRT5 and acute myeloid leukemia.